Vencor, Inc. 10-Q Summary: Quarter Ended March 31, 1997
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 1997, for Vencor, Inc., a major provider of healthcare services for the elderly. The company operates hospitals, nursing centers, contract services (Vencare), and assisted living communities (Atria). A significant event during the period was the completion of the acquisition of TheraTx, Incorporated on March 21, 1997, for approximately $336 million in cash.
Key Financial Metrics
- Revenue: $680.7 million for the quarter, an 8.7% increase from $626.3 million in the prior year period.
- Net Income: $31.7 million ($0.45 per diluted share), compared to $27.6 million ($0.39 per share) in the prior year.
- Income from Operations: $34.0 million, representing a 23% increase year-over-year.
- Cash Flow: Net cash provided by operating activities was $60.0 million, up from $38.0 million in the prior year.
- Liquidity: Cash and cash equivalents totaled $111.3 million. Working capital increased to $427.7 million from $320.1 million at year-end 1996.
- Debt: Long-term debt increased significantly to $1.29 billion (excluding current portion) due to the TheraTx acquisition. The company established a new $1.75 billion credit facility, with $1 billion outstanding at quarter-end.
- Extraordinary Items: An after-tax extraordinary loss of $2.3 million ($0.03 per share) was recorded related to the extinguishment of debt.
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by a 19.1% increase in hospital revenues (due to higher patient days and improved mix) and a 20.3% increase in Vencare contract services (partially due to TheraTx).
- Acquisition Impact: The TheraTx merger added 26 nursing centers and significant rehabilitation therapy contracts. Pro forma revenue for the quarter would have been $774.7 million had the acquisition occurred at the start of 1996.
- Asset Base: Accounts receivable increased to $584.3 million (from $420.8 million), extending days sales outstanding to 65 days from 54 days, largely due to the longer collection cycle of rehabilitation contracts acquired from TheraTx.
- Divestitures: The company sold 25 of 34 planned underperforming nursing centers during the quarter.
Outlook, Risks, and Management Commentary
- Capital Expenditures: Management plans to spend $200 million to $250 million in 1997 (excluding acquisitions) on facility improvements and Atria expansion. Approximately $200 million is earmarked over two years to upgrade nursing centers for higher acuity patients.
- Regulatory Risks: The Health Care Financing Administration (HCFA) issued a proposed rule regarding Medicare reimbursement for therapy services. Management believes the proposed guidelines will not materially adversely affect operating margins.
- Legislative Risks: Ongoing congressional proposals to reduce Medicare and Medicaid expenditures pose uncertainty, though the impact is currently unpredictable.
- Debt Refinancing: The company initiated a repurchase offering for TheraTx convertible notes, expecting an additional after-tax loss of approximately $2 million.
- Liquidity Position: Management asserts that operating cash flows and available credit facilities ($662 million under Vencor facility and $110 million under Atria facility) are sufficient to meet future needs.
Investor Verification Checklist
- Verify the integration progress and revenue contribution of the TheraTx acquisition, specifically regarding the 3-month collection cycle for rehabilitation contracts.
- Monitor the finalization of the HCFA proposed rule on therapy reimbursement and its potential impact on Vencare margins.
- Track the execution of the $200 million facility improvement plan and its effect on nursing center occupancy and patient mix.
- Review the status of the remaining 9 nursing centers pending sale and the regulatory approvals required.
- Confirm compliance with financial covenants in the new $1.75 billion credit facility, particularly regarding debt limits and stock repurchases.